Naim Alkhouri, MD, spoke to the potential for glucagon-like peptide-1 (GLP-1) receptor agonists to transform the treatment landscape for patients with metabolic dysfunction-associated steatohepatitis ...

Chances are, you haven’t heard of metabolic dysfunction–associated steatohepatitis (MASH)—but you’ve almost definitely heard ...

Wegovy and Ozempic are both semaglutide weight loss medications, but they’re prescribed differently based on who qualifies.

Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...

GLP-1 receptor agonists remain blockbuster drugs for weight management for people with overweight or obesity. Increasingly, ...

Results showed that 62.9% of patients on Ozempic saw a reduction in liver inflammation, compared to 34.3% on placebo.

Semaglutide, a GLP-1 receptor agonist sold under brand names Wegovy and Ozempic, is approved for weight loss and blood sugar ...

Research revealed that medications widely used for diabetes and obesity may offer significant benefits for patients with ...

Interim results from the Phase III ESSENCE trial published in The New England Journal of Medicine show once-weekly ...

A study has found that Ozempic may reverse signs of a disease that contributes to 2,000,000 deaths per year. New research has ...

A major clinical trial reveals Wegovy a popular weight loss drug also treats serious liver disease MASH—reducing liver inflammation and scarring in most patients ...